SM_165a: Pulmonary Hypertension Flashcards
Group 1 pulmonary hypertension is _______
Group 1 pulmonary hypertension is pulmonary arterial hypertension
(associated with connective tissue disease)
Group 2 pulmonary hypertension is _______
Group 2 pulmonary hypertension is pulmonary hypertension owing to left heart disease
(left sided pressures high so right sided pressures high)
Group 3 pulmonary hypertension is _______
Group 3 pulmonary hypertension is pulmonary hypertension owing to lung disease or hypoxia
Group 4 pulmonary hypertension is _______
Group 4 pulmonary hypertension is chronic thromboembolic pulmonary hypertension
(abnormal V/Q scan)
Group 5 pulmonary hypertension is _______
Group 5 pulmonary hypertension is pulmonary hypertension with unclear multifactorial mechanisms
Normal CVP is _____ mmHg
Normal CVP is <8 mmHg
Normal RAP is _____ mmHg
Normal RAP is 2-8 mmHg
Normal RV pressure is _____ mmHg
Normal RV pressure is 20-30 mmHg systolic and less than RAP diastolic
Normal PA pressure is ______
Normal PA pressure is 20-25 / 5-15 mmHg
(mean = 14 mmHg)
Normal PCWP is _____ mmHg
Normal PCWP is 6-12 mmHg
Normal LV pressure is ____ mmHg
Normal LV pressure is 120 / 6-12 mmHg
Normal LAP is ____ mmHg
Normal LAP is 6-10 mmHg
Class 1: PAH
- mPAP at rest:
- PCWP:
- PVR:
Class 1: PAH
- mPAP at rest: ≥ 25 mmHg
- PCWP: ≤ 15 mmHg
- PVR: > 3 Wood
Class 2: PVH
- mPAP at rest:
- PCWP:
Class 2: PVH
- mPAP at rest: ≥ 25 mmHg
- PCWP: ≥ 15 mmHg
Class 3: PH associated with lung disease
- mPAP at rest:
Class 3: PH associated with lung disease
- mPAP at rest: > 25 mmHg
- Underlying chronic lung disease
Class 4: PH CTEPH
- mPAP at rest:
- PCWP:
Class 4: PH CTEPH
- mPAP at rest: > 25 mmHg
- PCWP: ≤ 15 mmHg
- Evidence of chronic perfusion defects
Class 1: PAH
Pathology
Class 1: PAH
Pathology
- Smooth muscle hypertrophy
- Neointima formation (neo-vascularization)
- Endothelial cell proliferation (monoclonality)
*
Class 2: PVH
Pathology
- *
Class 2: PVH
Pathology
- Medial thickening
- Occlusive venopathy
Class 3: PH associated with lung disease
Pathology
- *
Class 3: PH associated with lung disease
Pathology
- Factor VIII staining
- Smooth muscle hypertrophy
Class 4: PH CTEPH
Ventilation ___ perfusion
Class 4: PH CTEPH
Ventilation > perfusion
Where is the lesion in each type of PH?
- Group 1: pulmonary arteries (smaller)
- Group 2: pulmonary veins
- Group 3: capillaries (parenchymal lung disease)
- Group 4: arteries in lungs (larger)

Echocardiographic changes in Group 1 pulmonary hypertension are _____ sided
Echocardiographic changes in Group 1 pulmonary hypertension are right sided
(enlargement of RA and RV, poorly functioning RV)
Group 1 is PAH

Echocardiographic changes in Group 2 pulmonary hypertension are _____ sided
Echocardiographic changes in Group 2 pulmonary hypertension are left sided
(reduced LV EF and dilated LA)
Group 2 is PVH

Compare and contrast features of PAH and PVH

Normal V/Q scan makes CTEPH ______
Normal V/Q scan makes CTEPH unlikely
(CT scan may underestimate the degree of obstruction in CTEPH)

The gold standard in the diagnostic work up of pulmonary hypertension is _____
The gold standard in the diagnostic work up of pulmonary hypertension is right heart catheterization
- direct measurement of RAP, PAP, PCWP, CO
- calculation of PVR and CI
- detetermination of intracardiac shunt
- determination of acute vasodilator activity

Why is characterizing the type of pulmonary hypertension important?
- Therapies differ drastically between groups
- Incorrect treatment can worsen a patient’s clinical status
- PAH treatments are costly
PVH is _____ common, while PAH is _____ common
PVH is very common, while PAH is not common
Presenting symptoms of PAH are often _____
Presenting symptoms of PAH are often non-specific
Group 1 pulmonary hypertension (PAH) is treated with _______
Group 1 pulmonary hypertension (PAH_ is treated with pulmonary vasodilator therapy
(dilates pre-capillary bed, meaning the small pulmonary arteries)
Treatment of Group 1 pulmonary hypertension (PAH) centers on three pathways: ______, ______, and ______
Treatment of Group 1 pulmonary hypertension (PAH) centers on three pathways: endothelin pathway, nitric oxide pathway, prostacyclin
- Endothelin promotes vasoconstriction - downregulated in treatment
- Nitric oxide promotes vasodilation - upregulated in treatment
- Prostacyclin promotes vasodilation - upregulated in treatment

Group 2 pulmonary hypertension (PVH) is treated by ______ and with _______
Group 2 pulmonary hypertension (PVH) is treated by optimizing heart failure medications and with diuresis
(PDE-5 may be useful)
Pulmonary vasodilators are not used in treatment of Group 2 pulmonary hypertension (PVH) because of ______
Pulmonary vasodilators are not used in treatment of Group 2 pulmonary hypertension (PVH) because of theoretical risk of pulmonary edema
Group 3 pulmonary hypertension (PH lung disease) is treated by ______ and _______
Group 3 pulmonary hypertension (PH lung disease) is treated by optimizing lung disease medications and reversing hypoxia
(PDE-5 may be useful)
Pulmonary vasodilators are not used in treatment of Group 3 pulmonary hypertension (PH lung disease) because of ______
Pulmonary vasodilators are not used in treatment of Group 3 pulmonary hypertension (PH lung disease) because of theoretical risk of increasing V/Q mismatching and worsening hypoxemia
(no clear benefit from PAH specific therapy and trend toward increased oxygen requirement for Group 3 patients)
Group 4 hypertension (CTEPH) is treated with ______, ______, and ______
Group 4 hypertension (CTEPH) is treated with anticoagulation, pulmonary vasodilators in non-operative candidates, and thromboendarterectomy
Group 2 pulmonary hypertension (PVH) and Group 3 pulmonary hypertension (PH lung disease) would be sometimes referred to as _______
Group 2 pulmonary hypertension (PVH) and Group 3 pulmonary hypertension (PH lung disease) would be sometimes referred to as “out of proportion”

What is lung disease with severe PH?
- Minority of chronic lung disease patients suspected to have severe vascular abnormalities
- Circulatory impairment is primary driver of reduced exercise capacity rather than ventilatory impairment related to lung disease
